Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CC-220 (Iberdomide) Alone and with Anti-CD20 mAbs in R/R Lymphoma
NCT04464798Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Nov 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of iberdomide in lymphoma (7 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose. Started Nov 2020; status: terminated.
02
Drugs
iberdomide
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT04464798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464798.